ABSTRACT
INTRODUCTION
Preterm birth (PTB) is the leading cause of neonatal morbidity and mortality 1 ; twin pregnancy is associated with a high rate of PTB. Prediction of PTB and interventions based on this prediction are the basis for effective prevention. Cervical length (CL) on second-trimester transvaginal sonography (TVS) is currently one of the best predictive tests for spontaneous PTB, including in twin gestations 2, 3 . Unfortunately, evidence for the effectiveness of interventions based on short TVS-CL in twin pregnancies is limited. The three most commonly studied interventions have been vaginal progesterone, cerclage and pessary placement [4] [5] [6] [7] [8] [9] [10] [11] . None of these interventions has consistently shown effectiveness and none is currently recommended by the American College of Obstetricians and Gynecologists, the Society for Maternal-Fetal Medicine or the Royal College of Obstetricians and Gynaecologists [12] [13] [14] . In particular, three randomized controlled trials (RCTs) that reported data on pessary placement for short TVS-CL in twin pregnancies showed contradicting results, and a recent meta-analysis of these three RCTs showed no benefit of pessary placement in women with a twin gestation and short TVS-CL [8] [9] [10] [11] . The objective of this study was to evaluate whether pessary placement prevents PTB in twin gestations with a short mid-trimester TVS-CL.
METHODS

Study design and participants
This was a multicenter open-label randomized controlled trial of asymptomatic women with a twin gestation. Institutional review board approval from each participating center and a Federal Drug Administration Investigational Device Exemption were obtained. Asymptomatic women aged 18-50 years with a dichorionic or monochorionic, diamniotic twin gestation were screened for TVS-CL at 18 + 0 to 23 + 6 weeks' gestation (the time of the fetal anatomy scan) and then at subsequent scheduled ultrasound scans prior to 28 + 0 weeks at three sites between 2 April 2014 and 30 June 2016. Initial oral consent for participating in the study was obtained at two of the three sites for TVS-CL, as TVS-CL screening in twins was not performed there before the start of this RCT. The third center routinely performed TVS-CL screening before the RCT started. TVS-CL was performed by sonographers using the CLEAR criteria of the Perinatal Quality Foundation 15 . Women with singleton or higher-order multiple gestations, monoamniotic twins, twin-twin transfusion syndrome, early selective intrauterine growth restriction (IUGR), ruptured membranes, lethal fetal structural anomaly, fetal chromosomal abnormality, present or planned cerclage, vaginal bleeding, suspicion of chorioamnionitis, ballooning of membranes outside the cervix into the vagina, TVS-CL of 0 mm, painful regular uterine contractions or placenta previa were excluded.
All eligible women found to have a TVS-CL of ≤ 30 mm before 28 + 0 weeks were offered randomization to receive pessary placement or no pessary. A digital cervical examination was performed prior to randomization. After counseling, written consent was obtained from eligible women identified by trained personnel as having a TVS-CL of ≤ 30 mm at any TVS screening assessment before 28 + 0 weeks. A TVS-CL of ≤ 30 mm was chosen as the cut-off, given its higher sensitivity for predicting PTB compared with that of a TVS-CL of ≤ 25 mm, and the overall good predictive accuracy by both receiver-operating characteristics curve and logistic regression analyses in our previous population of twins 2 . Consenting women were randomized centrally by a web-based system (REDCap™) using random blocks of two, four and six women to receive or not to receive a pessary. Randomization was stratified by gestational age (18 + 0 to 23 + 6 vs 24 + 0 to 27 + 6 weeks), study site and chorionicity (monochorionic vs dichorionic). No other treatment (e.g. vaginal progesterone or cerclage) was recommended to women with a TVS-CL of ≤ 30 mm. The pessary was not available at sites outside the trial.
Pessaries were inserted by maternal-fetal medicine staff centrally trained in proper placement. Training in pessary insertion consisted of a didactic session and a hands-on session, and all staff were required to demonstrate competence in pessary placement on a live model. The Bioteque™ cup pessary was used (Bioteque, Fremont, CA, USA). This pessary is very similar to the Arabin pessary ( Figure 1 ). The size of pessary required was determined by a pelvic examination prior to pessary placement. Subjects were contacted monthly to ascertain information including hospital and office visits other than routine prenatal care appointments and potential complications and symptoms related to the pessary. While there was no specific screening at randomization or follow-up, any genitourinary infection, such as urinary tract infection, bacterial vaginosis, chlamydia, gonorrhea, genital herpes simplex virus (primary or recurrent), trichomonas or syphilis diagnosed during the current pregnancy, were recorded. Indications for pessary removal before 36 weeks included patient request, preterm prelabor rupture of membranes (PPROM), labor and vaginal bleeding. Pessaries were otherwise routinely removed during the 36 th week of gestation.
Outcome measures
The primary outcome was PTB < 34 weeks. Planned secondary maternal outcomes included PTB < 37, < 32, < 28 and < 24 weeks, spontaneous PTB < 37, < 34, < 28 and < 24 weeks, gestational age at delivery, birth weight, chorioamnionitis, genitourinary infection and Cesarean delivery. Spontaneous PTB included those with spontaneous onset of labor and those with rupture of membranes prior to labor. Neonatal outcomes included neonatal death (death between birth and 28 days of age) and a composite adverse neonatal outcome that consisted of necrotizing enterocolitis, intraventricular hemorrhage (Grade 3 or 4), respiratory distress syndrome, bronchopulmonary dysplasia, retinopathy, blood culture-proven sepsis and neonatal death. Data were collected regarding potential significant adverse maternal effects, including heavy vaginal bleeding, injury (e.g. erosion or fistula) to the vagina, cervix or bladder and uterine rupture, as well as maternal intolerance of the pessary (request for removal secondary to discomfort and/or discharge).
Sample size calculation
Calculation of sample size was based on a reduction in rate of delivery before 34 weeks from 40% 2, 16 in the expectant management group to 20% 8 in the pessary group, with a power of 80%. To detect this difference at a significance level of 5%, 164 subjects were required. However, the Data and Safety Monitoring Committee recommended that subject recruitment be stopped on 30 June 2016, owing to the fact that two of the three sites could not recruit any more women to the trial, given the precedence of a competing National Institute of Child Health and Human Development (NICHD) Maternal Fetal Medicine Unit Network (MFMU) pessary trial after their entrance into the NICHD MFMU Network. No interim analysis was performed.
Statistical analysis
Statistical analysis was based on the intention-to-treat principle. Comparisons between the two groups were carried out by the Mann-Whitney U-test and Fisher's exact test. P-values for all hypotheses were two sided and P < 0.05 was considered to be statistically significant. The risk of PTB before 34 weeks was quantified by use of relative risk (95% CI). Multivariate analysis was performed by logistic regression. The interval between randomization and delivery was assessed by Kaplan-Meier analysis, in which gestational age was the timescale, PTB the event and non-indicated deliveries were censored. Statistical analysis was performed using SPSS v23.0 (IBM Corp., Armonk, NY, USA). This study was reported following the CONSORT guidelines and was registered on ClinicalTrials.gov, number NCT 02056639.
RESULTS
A total of 421 women with a twin gestation were screened by TVS-CL. Eighty-five (20%) women had a TVS-CL of ≤ 30 mm before 28 + 0 weeks' gestation ( Figure 2 ). Of these, 80 (94%) met the eligibility criteria and 46 (58%) of the eligible subjects agreed to randomization -33 (72%) before 24 weeks at their first TVS-CL screening and 13 (28%) at 24 + 0 to 27 + 6 weeks. Twenty-three (50%) women were randomized to pessary placement and 23 (50%) to no pessary. Demographic characteristics, including mean gestational age and mean CL at randomization, were similar in both groups, except for level of education and mode of conception (Table 1) . Of the 23 women who were randomized to receive a pessary, 12 had a #3 Bioteque pessary and 11 a #4 Bioteque pessary. Three women received vaginal progesterone (two controls and one in the pessary group) and none received cerclage. There was no significant difference between the pessary and no-pessary groups in the primary outcome, PTB < 34 weeks (39% vs 35%; relative risk, 1.13 (95% CI, 0.53-2.40); P = 1.00), as well as other obstetric and neonatal outcomes (Tables 2 and 3 ). Adjustment of PTB outcomes for differences in baseline characteristics (maternal age, education and type of conception) had no effect on the lack of impact of the intervention on outcomes. The Kaplan-Meier survival curve also failed to show a significant difference between the pessary and control groups (Figure 3 ). The mean time to delivery was 11.6 (95% CI, 9.5-13.7) weeks in the pessary group and 11.7 (95% CI, 9.5-14.0) weeks in the no-pessary group (log-rank test: P = 0.81). Nineteen (83%) subjects in the pessary group and 10 (43%) in the no-pessary group reported vaginal discharge on at least one of the monthly phone calls after enrollment. Sixteen (70%) of the 23 subjects in the pessary group had their pessary removed before 36 weeks. Ten women had pessary removal owing to PPROM, and all delivered before 36 weeks. Two women were delivered in the 35 th week owing to pre-eclampsia and one delivered at 33 weeks secondary to IUGR of both twins with non-reassuring fetal surveillance. Three women requested pessary removal because of their symptoms. Two had their pessary removed because of discomfort and vaginal pressure; one removed the pessary herself at 29.1 weeks and subsequently delivered at 36.9 weeks' gestation, and the other had her pessary removed at 27.3 weeks and had spontaneous PTB at 28.9 weeks. A third woman had her pessary removed at 31.9 weeks because of odor, vaginal discharge and cramping, and had spontaneous PTB at 35.9 weeks. One woman randomized to the no-pessary group had a pessary placed owing to an error. Her pessary was removed at 36 weeks and she delivered at 36.9 weeks. She reported vaginal discharge. The woman who removed her own pessary was noted to have a minor vaginal sidewall abrasion after removal of the pessary. There were no other complications associated with pessary insertion or removal.
Three women who received a pessary developed a urinary tract infection, compared with one in the no-pessary group (Table 4) . Women with a pessary had more vaginal infections than did women in the no-pessary group, but this difference was not statistically significant. Three women who received a pessary experienced chorioamnionitis compared with none in the no-pessary group.
DISCUSSION
The Bioteque pessary had no effect on the incidence of PTB before 34 weeks' gestation in twin gestations with a TVS-CL of ≤ 30 mm. The pessary appeared to be safe and was well tolerated overall by the majority of women, despite the high reported rate of vaginal discharge.
Three other RCTs have been published so far reporting data on pessary insertion for short mid-trimester TVS-CL in twin pregnancies [8] [9] [10] . All women were screened in the second trimester (16-24 weeks), but different TVS-CLs were used as cut-off: ≤ 38 mm 8 and ≤ 25 mm 9, 10 . Only one RCT specifically studied twin gestations with a short CL and the effect of pessary placement 10 , while the other Table 2 Pregnancy outcome and relative risk (RR) for preterm birth (PTB) and spontaneous PTB (sPTB) in 46 women with twin gestation and cervical length ≤ 30 mm on transvaginal sonography who were randomized to receive pessary or no pessary Data are given as n (%) or median (interquartile range). GA, gestational age; PPROM, preterm prelabor rupture of membranes. Data are given as n (%) or median (interquartile range). Data are given as n. *One woman in no-pessary group who had a pessary placed erroneously was included in the pessary group; she had bacterial vaginosis, yeast infection and chorioamnionitis. HSV, genital herpes simplex virus.
two reported the effects of pessaries on twin gestations with a short CL as subanalyses of larger RCTs on the effect of a pessary in all twin gestations 8, 9 . All three RCTs used the Arabin pessary as the intervention. One RCT (n = 133 twin pregnancies with TVS-CL ≤ 38 mm) reported significant decreases in PTB < 28 and < 32 weeks (but not < 37 weeks) and better composite neonatal outcomes in the pessary group than in the no-pessary group 8 . The second RCT (n = 214 twin pregnancies with TVS-CL ≤ 25 mm) reported no significant difference in PTB or neonatal outcome between groups 9 . The third RCT (n = 134 twin pregnancies with TVS-CL ≤ 25 mm) reported a significant decrease in PTB < 34 weeks (but not < 37 weeks) and similar composite neonatal outcomes in both groups 10 . A meta-analysis of these three RCTs showed no significant effect on PTB or neonatal outcome of pessary placement in twin pregnancies with mid-trimester short TVS-CL 11 . Our RCT confirms the results of the largest of the RCTs considered and of the meta-analysis of all three 9, 11 . In our study, the pessary group had a shorter median CL at randomization than did the no-pessary group (16.7 vs 22.9 mm), but this difference did not reach statistical significance, although a CL of < 20 mm has been associated with a greater risk for PTB compared with a longer CL 3 . Regarding safety of the pessary, our study found the pessary to be safe, as did the other three RCTs. Three (13%) of the women requested pessary removal. The only significant finding was an expected increase in women reporting vaginal discharge. Six (26%) women who received a pessary experienced at least one vaginal infection compared with one (4%) in the group that did not receive a pessary, with no statistically significant difference for any of the infections, including urinary tract infection, vaginal infection and chorioamnionitis (Table 4 ). The rate of vaginal infection (26%) in women receiving a pessary in our study is similar to that (21%) reported in the largest pessary trial 9 , but whether any of these infections was related to pessary placement is unclear.
The strengths of our study include its randomized design and its high methodological rigor, following CONSORT guidelines. Other strengths include our hands-on training and requirement for all staff to demonstrate competence in pessary insertion on a live model. The distribution of TVS-CL and the incidence of short TVS-CL were similar to those in most similar studies 2, 3, 16 .
The main limitation of our study was the fact that it was stopped before planned enrollment was complete, which resulted in a small sample size. Two demographic characteristics were found to be different between the groups, but logistic regression accounting for these differences failed to affect the results. Our sample size precluded us from making planned subgroup analyses based on the degree of short CL, chorionicity, gestational age at identification of short CL or prior PTB. Although we used a pessary (Bioteque) that differed from the pessaries (Arabin) used in previous RCTs [8] [9] [10] on the prevention of PTB in twin pregnancies with a short cervix, they are similar in shape ( Figure 1 ). Their dimensions for the width of both the outer and inner rings are similar (#3 Bioteque pessary, 65 × 33 × 17 mm vs Arabin pessary, 65 × 32 × 25 mm 10 ), however, the height of the Bioteque pessary is less and we do not know if this difference is of clinical significance. The pessary removal rate of 70% in our study occurred mostly because of preterm labor or PPROM before 36 weeks (10/16 cases, 63%), with only three (13%) women requesting pessary removal because of symptoms. In two RCTs on pessaries for the prevention of PTB in twin pregnancies, rates of pessary removal were not reported for the subgroups with short TVS-CL, but only for the overall population of all twin pregnancies; rates of pessary removal were 46% before 36 weeks and 22% before 34 weeks 8, 9 . In the third RCT that evaluated pessaries in twin pregnancies with a short cervix, pessary removal before 36 weeks was not reported separately; pessary removal must have occurred before 34 weeks in the 18% of women with twins and a short cervix who had pessary placement and delivered before this gestational age 10 . If our study had included the planned sample size, 14% or fewer of the residual 59 subjects in the pessary arm would have had to deliver before 34 weeks' gestation (compared to maintaining the 35% PTB < 34 weeks in the control arm) in order to detect a significant difference in the primary outcome.
In conclusion, treatment with a cervical pessary did not prevent PTB in women with a twin gestation and a TVS-CL of ≤ 30 mm before 28 weeks in this small underpowered RCT. Although the power of the study to draw any firm conclusions regarding the effectiveness of pessary placement in preventing PTB was limited because of its limited sample size, our results confirm those of the largest RCT and the meta-analysis of the three published RCTs on this topic 9, 11 . There are currently several ongoing RCTs on the effect of pessaries in twin pregnancies with short TVS-CL, and addition of new data will be welcomed and will help to clarify the ongoing controversy given by two positive trials 8, 10 and two negative trials (that of Nicolaides et al. 9 and the present study), and will allow investigators to explore subgroup analyses. A prospective individual patient-level data meta-analysis (Prospective Meta-analysis for Pessary Trials, PROMPT) is planned.
